OraSure Technologies (NASDAQ: OSUR) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare OraSure Technologies to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.
Insider & Institutional Ownership
92.1% of OraSure Technologies shares are held by institutional investors. Comparatively, 63.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 6.4% of OraSure Technologies shares are held by company insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
OraSure Technologies has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, OraSure Technologies’ rivals have a beta of 1.08, suggesting that their average share price is 8% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for OraSure Technologies and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|OraSure Technologies Competitors||322||1477||2588||105||2.55|
OraSure Technologies currently has a consensus target price of $15.21, suggesting a potential downside of 30.81%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.93%. Given OraSure Technologies’ rivals higher possible upside, analysts clearly believe OraSure Technologies has less favorable growth aspects than its rivals.
This table compares OraSure Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|OraSure Technologies Competitors||-128.72%||-37.35%||-10.53%|
Valuation and Earnings
This table compares OraSure Technologies and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|OraSure Technologies||$135.07 million||$23.92 million||40.70|
|OraSure Technologies Competitors||$827.05 million||$159.46 million||33.79|
OraSure Technologies’ rivals have higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
OraSure Technologies beats its rivals on 8 of the 13 factors compared.
About OraSure Technologies
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.